Have your say about getting SIMPONI (golimumab) on the PBS listing for treatment of ulcerative colitis
Submissions due by Wednesday 4 October 2017
Crohn’s & Colitis Australia urges its members to have their say about the potential listing of Simponi on the Pharmaceutical Benefits Scheme (PBS) for the treatment of ulcerative colitis.
The manufacturers of Simponi have recently made an application to Pharmaceutical Benefits Advisory Committee (PBAC) for their product to be made available to patients through the PBS for the treatment of adult patients with moderate to severe ulcerative colitis.
SIMPONI is an anti-tumour necrosis factor (TNF) alpha treatment delivered through under the skin injection once-monthly. The therapy is effective and offers patients a convenient option for a self-administered anti-TNF, especially helpful for those who have to travel a long distance to receive infusions.
Simponi has been approved by the Therapeutic Goods Administration for use in Australia, and is currently being used for patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The therapy is not currently available through the PBS, making it prohibitively expensive for most Australians.
As part of its evaluation of products the PBAC asks for public comments from patients, carers, members of the public, health professionals or consumer interest groups. These comments help the PBAC assess if the community needs access to therapies.
If you are a patient, family, friend of carer for someone living with ulcerative colitis, you able to have their say on whether this additional treatment for people with moderate and severe ulcerative colitis should be made available through subsidy on the PBS – the main mechanism via which the Government subsidises the cost of medications used by the community.
Crohn’s & Colitis Australia has written a letter of support to the PBAC recommending the listing of Simponi on the PBS.
If you wish to make a comment they can do so by accesing the consumer form below. Please indicate the ‘Medicine to which your submission relates’ as SIMPONI and ‘date of the PBAC meeting’ as November 2017.
CCA would also like to hear your comments and personal stories so that we can better advocate for your needs. Please email all comments to email@example.com